HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Montastruc, J. L. Articles by Rascol, A. Search for Related Content PubMed PubMed Citation Articles by Montastruc, J. L. Articles by Rascol, A.

Parkinson's disease and hypertension

Chronic bromocriptine treatment

From the Laboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine (Prof. Montastruc), Service de Médecine Interne, C.H.U. Purpan (Dr. Chamontin), and Service de Neurologie, C.H.U. Purpan (Pr. Rascol). Toulouse, France.

We studied the effects of bromocriptine therapy (mean dosage, 56.0 mg daily) for 12 months in five patients with both Parkinson's disease and hypertension. Therapy improved neurologic manifestations and reduced both supine and standing systolic blood pressures and standing diastolic blood pressure with no consistent change in heart rate. Transient episodes of orthostatic hypotension appeared in two cases. Domperidone (60 mg daily for 1 month) did not abolish the antihypertensive effect of bromocriptine, suggesting that central dopaminergic or alpha-adrenolytic mechanisms are involved in this effect. Bromocriptine may be useful in the treatment of hypertension in patients with Parkinson's disease.

Address correspondence and reprint requests to Prof. Montastruc, Laboratoire de Pharmacologie Médicale et Clinique, Faculté de MeAdecine, 37 Allées Jules Guesde, 31000 Toulouse, France.

Accepted for publication February 7, 1985